NYSEAMERICAN:OGEN Oragenics (OGEN) Stock Forecast, Price & News $2.91 -0.11 (-3.64%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$2.85▼$3.0150-Day Range$2.94▼$4.1852-Week Range$2.60▼$17.40Volume2,467 shsAverage Volume7,098 shsMarket Capitalization$7.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Oragenics (NYSEAMERICAN:OGEN) StockOragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Read More OGEN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OGEN Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comOragenics (NYSEAMERICAN:OGEN) Coverage Initiated by Analysts at StockNews.comSeptember 15, 2023 | americanbankingnews.comOragenics (NYSEAMERICAN:OGEN) Now Covered by StockNews.comSeptember 24, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 7, 2023 | finance.yahoo.comOragenics, Inc. Announces Private PlacementJune 5, 2023 | finance.yahoo.comOragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDMMarch 29, 2023 | finance.yahoo.comOragenics to Participate in the World Vaccine Congress WashingtonMarch 14, 2023 | finance.yahoo.comOragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VREMarch 8, 2023 | finance.yahoo.comOragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership TeamSeptember 24, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.March 1, 2023 | finance.yahoo.comOragenics Looks To Boost Potency Of Its Nasal COVID-19 Vaccine With New Licensing PactMarch 1, 2023 | finance.yahoo.comOragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine CandidateFebruary 3, 2023 | financialpost.comOragenics, Inc. Regains Compliance with NYSE AmericanDecember 23, 2022 | finance.yahoo.comOragenics, Inc. Discloses One-for-Sixty Reverse Stock SplitDecember 22, 2022 | finance.yahoo.comOragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine CandidateDecember 20, 2022 | finance.yahoo.comOragenics, Inc. Receives NYSE American NoticeDecember 19, 2022 | financialpost.comOragenics, Inc. Announces New ChairOctober 24, 2022 | finance.yahoo.comOragenics to Participate in the 2022 BioFlorida Annual ConferenceSeptember 30, 2022 | benzinga.comOral & Dental Probiotics Market Size & Shares by 2027 | Revenue, Cost Analysis, Gross Margins, Future Inv - BenzingaSeptember 9, 2022 | morningstar.comOragenics Inc OGEN Stock QuoteSeptember 7, 2022 | reuters.comOGEN.P - Oragenics Inc | Stock Price & Latest News | ReutersAugust 30, 2022 | reuters.comOGEN.A - Oragenics Inc | Stock Price & Latest News | ReutersAugust 24, 2022 | benzinga.comOragenics Announces Preliminary Toxicology Data For Intranasal COVID-19 Vaccine Candidate; Says 'N T-CoV2 - BenzingaAugust 24, 2022 | businesswire.comOragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate - Business WireAugust 24, 2022 | finance.yahoo.comOragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine CandidateAugust 24, 2022 | seekingalpha.comOGN stock on watch after early toxicology data for intranasal COVID-19 shot (NYSE:OGN) - Seeking AlphaJuly 29, 2022 | marketscreener.comORAGENICS INC - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. - Marketscreener.comJuly 8, 2022 | marketscreener.comORAGENICS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.comSee More Headlines Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Email Address OGEN Company Calendar Last Earnings8/14/2023Today9/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:OGEN CUSIPN/A CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,290,000.00 Net MarginsN/A Pretax Margin-10,347.41% Return on Equity-128.11% Return on Assets-95.28% Debt Debt-to-Equity RatioN/A Current Ratio7.10 Quick Ratio7.10 Sales & Book Value Annual Sales$130,000.00 Price / Sales56.86 Cash FlowN/A Price / Cash FlowN/A Book Value$5.64 per share Price / Book0.52Miscellaneous Outstanding Shares2,540,000Free Float2,333,000Market Cap$7.39 million OptionableNot Optionable Beta0.52 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Kimberly M. Murphy (Age 60)Pres, CEO & Director Comp: $550.93kDr. Martin Handfield M.Sc. (Age 52)Ph.D., Chief Scientific Officer Comp: $264.77kMs. Janet Huffman (Age 51)CFO, Sec. & Treasurer Key CompetitorsApplied Molecular TransportNASDAQ:AMTIBiodexa PharmaceuticalsNASDAQ:BDRXLexaria BioscienceNASDAQ:LEXXAdamis PharmaceuticalsNASDAQ:ADMPProtagenic TherapeuticsNASDAQ:PTIXView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCSold 4,077 shares on 8/11/2023Ownership: 0.649%Robert C KoskiSold 813 sharesTotal: $9,756.00 ($12.00/share)Robert C KoskiSold 3,333 sharesTotal: $37,996.20 ($11.40/share)View All Insider TransactionsView All Institutional Transactions OGEN Stock - Frequently Asked Questions How have OGEN shares performed in 2023? Oragenics' stock was trading at $0.1051 at the beginning of 2023. Since then, OGEN shares have increased by 2,668.8% and is now trading at $2.91. View the best growth stocks for 2023 here. Are investors shorting Oragenics? Oragenics saw a decline in short interest in the month of August. As of August 15th, there was short interest totaling 23,400 shares, a decline of 23.8% from the July 31st total of 30,700 shares. Based on an average daily trading volume, of 10,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.0% of the company's shares are short sold. View Oragenics' Short Interest. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSEAMERICAN:OGEN) announced its earnings results on Monday, August, 14th. The biotechnology company reported ($1.51) earnings per share for the quarter. The biotechnology company had revenue of $0.01 million for the quarter. When did Oragenics' stock split? Oragenics shares reverse split on the morning of Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Imunon (CLSN), Jaguar Health (JAGX), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV). What is Oragenics' stock symbol? Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN." Who are Oragenics' major shareholders? Oragenics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.65%). Insiders that own company stock include Fred Telling, Joseph Hernandez, Michael O'keefe Sullivan and Robert C Koski. View institutional ownership trends. How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Oragenics' stock price today? One share of OGEN stock can currently be purchased for approximately $2.91. How much money does Oragenics make? Oragenics (NYSEAMERICAN:OGEN) has a market capitalization of $7.39 million and generates $130,000.00 in revenue each year. How can I contact Oragenics? Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The official website for the company is www.oragenics.com. The biotechnology company can be reached via phone at 813-286-7900, via email at johnm@coreir.com, or via fax at 813-286-7904. This page (NYSEAMERICAN:OGEN) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.